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Abstract
The C-terminal domain (CTD) of Hepatitis B virus (HBV) core protein is involved in regulating multiple stages of the HBV
lifecycle. CTD phosphorylation correlates with pregenomic-RNA encapsidation during capsid assembly, reverse
transcription, and viral transport, although the mechanisms remain unknown. In vitro, purified HBV core protein (Cp183)
binds any RNA and assembles aggressively, independent of phosphorylation, to form empty and RNA-filled capsids. We
hypothesize that there must be a chaperone that binds the CTD to prevent self-assembly and nonspecific RNA packaging.
Here, we show that HBV capsid assembly is stalled by the Serine Arginine protein kinase (SRPK) binding to the CTD, and
reactivated by subsequent phosphorylation. Using the SRPK to probe capsids, solution and structural studies showed that
SRPK bound to capsid, though the CTD is sequestered on the capsid interior. This result indicates transient CTD
externalization and suggests that capsid dynamics could be crucial for directing HBV intracellular trafficking. Our studies
illustrate the stochastic nature of virus capsids and demonstrate the appropriation of a host protein by a virus for a non-
canonical function.
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Introduction
Hepatitis B virus (HBV) is an enveloped DNA virus that causes
liver damage and can lead to cirrhosis and liver cancer [1]. It has
infected 2 billion people worldwide including 350 million chronic
carriers [2], making it a major health concern, and also leading to
social problems due to discrimination against the virus carriers
where the disease is endemic.
Despite the extensive impact of HBV, there has been no
effective treatment to eliminate the virus from carriers [3]. In part,
this is because the virus life cycle is not fully understood. The viral
infection starts with cell entry to release a viral core into the
cytoplasm [4]. The core is a T=4 icosahedral capsid of ,35 nm
diameter [5] containing a relaxed circular DNA (rcDNA) that is
partially double-stranded and covalently bonded to a reverse
transcriptase (RT). The core is transported to the nucleus where it
releases the rcDNA, which is deproteinated [6] and ‘repaired’ by
the host machinery to make a covalently-closed circular DNA
(cccDNA) [7,8]. Transcription of nuclear cccDNA generates the
replication intermediate (pregenomic RNA, pgRNA) and other
mRNAs [9]. PgRNA codes for core protein and RT. In the
cytoplasm, core proteins encapsidate a pgRNANRT complex to
form immature HBV cores [10]. Maturation occurs when pgRNA
is reverse-transcribed into rcDNA. Only mature cores are
transported to the ER to acquire an envelope for subsequent
secretion, or are delivered back to the nucleus for maintaining viral
infection [11,12].
The viral core protein is a critical regulatory factor of the HBV
life cycle. It is 183 amino acids in length, hence referred to as
Cp183. The first 149 amino acids comprise the assembly domain
[13] (Figure 1a). A core protein mutant consisting of this domain
only (Cp149) can self-assemble in vitro to give particles whose
capsid is indistinguishable from those of HBV virions [14].
However, Cp149 particles do not incorporate any nucleic acid
[15]. The last 34 residues of Cp183, i.e., the C-terminal domain
(CTD), are rich in serines and arginines, and are responsible for
interaction with RNA [16]. Phosphorylation of the serines,
particularly S155, S162 and S172, is required for specific
packaging of pgRNANRT in vivo [17–19]. Phosphorylation status
of Cp183 CTD was also found to be associated with intracellular
transport of HBV cores. Only phosphorylated HBV cores reached
the nucleus [20,21] and only mature cores were imported into the
nucleus [22]. Dephosphorylation was observed during HBV core
maturation and correlates with subsequent envelopment and
secretion [23–25].
We have studied Cp149 and Cp183 assembly in vitro [26].
Dimeric Cp149 is soluble and spontaneously assembles, in an
entropically driven reaction, into T=4 capsids as a function of
protein concentration, ionic strength and temperature [27]. In
contrast, dimeric Cp183 is not substantially soluble under
physiological conditions. To control in vitro assembly, we used
non-denaturing concentrations of guanidine hydrochloride
(GuHCl) to keep Cp183 dimers in solution (Figure 1B). Decreasing
the concentration of GuHCl induced capsid assembly along with
precipitation of some Cp183. We speculated that for in vivo HBV
core assembly to proceed in a regulated manner, a chaperone,
instead of GuHCl, would be required to keep newly expressed
Cp183 from precipitating, self-assembling, or assembling around
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the chaperone to allow assembly when the right assembly
nucleation center, RT-bound pgRNA, is available. Since Cp183
is phosphorylated prior to or during HBV core assembly [18], the
phosphorylating kinase may well act as a non-canonical chaper-
one.
One of the kinases suggested to phosphorylate Cp183 in vivo is a
memberoftheSRproteinkinase(SRPK)family.SRPKsspecifically
phosphorylate serines within the arginine/serine repeats (RS
domain) of an SR protein [28,29]. SR proteins share a remarkable
sequence similarity with the Cp183 CTD (Figure 1A) [30]. SR
proteins are RNA-binding molecules that have roles in spliceosome
positioning and RNA transport from the nucleus. SRPK1 and
SRPK2 were co-purified with GST-tagged HBV core proteins from
Huh-7 cell lysates, and they demonstrated kinase activity biochem-
ically identical to HBV core kinase activity in the cell lysate [31].
Interestingly, SRPKs were also shown to influence HBV life cycle
independent of kinase activity as overexpression of SRPK1 and
SRPK2, even catalytically inactive mutants, suppressed HBV
replication [32]. Though SRPK2 actually has the higher affinity
for HBV [32], a truncated form of SRPK1 has been exhaustively
characterized. SRPK1 binds to the typical substrate ASF/SF2 with
aK d , 50 nM and functions with a processive phosphorylation
mechanism [33,34]_ENREF_25. The structure of SRPK1 com-
prises a small N-terminal lobe of primarily connected by a spacer
region to a larger C-terminal lobe [35]. While the spacer is
important for subcellular localization [36], the two lobes constitute
the kinase core. A mutant lacking the spacer as well as part of the N-
terminal lobe, SRPK1DN1S1, has been shown to maintain
substrate specificity and kinase functionality in vitro [33,34].
In this article, we discuss in vitro studies of Cp183 interaction
with SRPK1DN1S1 (abbreviated as SRPKD in the rest of the
article). Using a column-based binding assay, we showed that
SRPKD bound to Cp183 at the CTD. When SRPKD bound to
Cp183 dimers, the core protein was unable to self-assemble;
assembly was subsequently reactivated when ATP-induced phos-
phorylation decreased the stability of the SRPK/Cp183 complex.
Thus, we demonstrated a kinase-gated mechanism of HBV
assembly where the kinase served as a non-canonical chaperone.
SRPKD also bound to Cp183 capsid. We established a centrifu-
gation-based titration assay to show the stoichiometry to be 4963
SRPKD per capsid. Image reconstructions of cryo-EM data
identified 30 multivalent SRPKD-binding sites at the capsid twofold
vertices. These sites coincide with pores in the capsid that are
proximal to the core protein CTDs. These observations indicate
that the CTD is transiently exposed to the capsid exterior, possibly
by threading through the pores. However, SRPKD did not bind to
RNA-filled capsid, implying tunable accessibility of Cp183 CTDs
depending on nucleic acid-capsid interaction. We suggest that
nucleic acid-sensitive exposure of the CTDs provides a mechanism
for directing the intracellular transport of HBV.
Results
SRPKD binding to HBV capsids requires the core protein
CTD
As a qualitative assay, we tested capsids for their ability to bind
His-tagged SRPKD adsorbed onto a Ni
++-column. Three types of
capsid were assayed: empty reassembled Cp183 capsid, empty
reassembled Cp149 capsid [14]_ENREF_6 and Cp183 capsid
filled with heterogeneous RNA from the expression system
[37]_ENREF_1 (see Supporting Figure S1).
Cp183 associated with column-bound SRPKD. Without
SRPKD pre-loaded to the Ni
++-column, empty Cp183 capsid
flowed through the column freely; however, a substantial fraction
of empty Cp183 capsid bound to the SRPKD-loaded column and
co-eluted with SRPKD, indicating interaction between the capsid
and SRPKD. The earlier fractions of the eluate were richer in
Cp183 than later ones, implying that binding of capsid weakened
the interaction of the His-tagged SRPKD with the Ni
++-column.
Moreover, it was observed that more Cp183 capsid bound to the
column when the flow rate was slowed from 0.5 ml/min to
0.3 ml/min or when the salt concentration was decreased from
0.5 M to 0.3 M (data not shown). The former observation showed
Figure 1. HBV core assembly and Cp183 phosphorylation. (A) A
representation of the core protein sequence, showing the assembly
domain (amino acids 1 to 149) and the nucleic acid-binding domain
(amino acids 150 to 183). The primary sequence of the nucleic acid-
binding domain contains 7 serines which are potential phosphorylation
sites by SRPK (red). In vivo, phosphorylation of S155, S162, and S170
(indicated by arrows) confers specificity for pgRNA packaging [17,18].
This panel is reproduced from reference [26] (Copyright  American
Society for Microbiology, J. Virol., 2010, 84, 7174-84, doi:10.1128/
JVI.00586-10). (B) Comparison between the in vitro and in vivo assembly
pathways. Neither unphosphorylated nor phosphorylated Cp183 dimers
(in dotted frames) are very soluble. Note the similar positions of GuHCl




A virus particle is a molecular machine that has evolved to
self-assemble within the confines of a living cell. For
hepatitis B virus (HBV), outside of a cell, the self-assembly
process is very aggressive and consequently not specific
for viral RNA. Here we show that HBV takes advantage of a
host protein, SRPK, which acts like a molecular chaperone,
to prevent the HBV core protein from binding RNA and to
prevent the core protein from assembling at the wrong
time and place. At the right time, SRPK can be removed in
a regulated reaction to allow assembly. Once a virus is
assembled, it must traffic to the right intracellular locale.
Using SRPK, we show that HBV cores can transiently
expose a segment of protein, normally inside the virus,
that carries a signal for transport to the host nucleus. This
is the first example we know of where a virus repurposes
an enzyme for an alternative function. This sort of interplay
between virus and host, where the virus hijacks and
repurposes host proteins, is likely to be a common feature
of viral infection.
A Non-Canonical Chaperone of HBV Assembly
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with a half-time on the order of minutes. The latter observation
suggested that the interaction between SRPKD and Cp183 capsid
is electrostatic in nature.
In contrast to empty Cp183 capsids, both Cp149 capsids and
RNA-filled Cp183 capsids ran through the Ni
++-column freely
with or without bound SRPKD. Cp149 is a core protein mutant
lacking the serine and arginine-rich CTD of Cp183. Its failure to
bind to the SRPKD-loaded column was consistent with our
assumption that the SR protein-like CTD is the substrate for
SRPK. In the case of RNA-filled Cp183 capsids, the interaction to
RNA probably traps the basic CTD inside and prevents its
interaction with the external SRPKD.
These studies raise the question of CTD accessibility on the
capsid exterior. Structural studies [38,39] and the internal location
of packaged nucleic acid imply that the CTDs are on the interior
of a Cp183 capsid. In order for it to be accessible to column-
adsorbed SRPKD, we are led to hypothesize that the CTD must at
least transiently penetrate through the capsid. Thus, the ionic
strength dependence of binding may also reflect a change in capsid
stability.
Multiple SRPKD molecules bind to a Cp183 capsid
To measure the binding stoichiometry and affinity between
SRPKD and Cp183 capsid, we titrated empty reassembled Cp183
capsid with SRPKD. The titration was to be plotted as n, the
average number of SRPKD per capsid, versus [S], the concen-
tration of unbound SRPKD. In the simplest model, all binding
sites on a capsid are equivalent and independent. The maximum
number of binding sites per capsid is N and the microscopic
dissociation constant is KD. The relationship between n and [S]
should lead to a hyperbolic curve
n~N: S ½ 
S ½  zKD
ð1Þ
Experimentally, we sedimented the capsids along with bound
SRPKD, and measured the concentration of SRPKD remaining in
the supernatant, [S]A, using densitometry of SDS-PAGE. In our
data sets, [S]A did not go beyond 200 nM, because of protein
precipitation at higher concentrations. To make sure that titration
data reflected binding to capsids, we also monitored reactions
using dynamic light scattering (data not shown). For
[S]A,200 nM, the light scattering always indicated a single
dominant species of , 40 nm, the hydrodynamic size of a Cp183
capsid. The scattering intensity grew with increasing [S]A due to
deposition of SRPKD on the capsids. As light scattering is
particularly sensitive to large complexes, this result does not
exclude the presence of dimer. As [S]A went above 200 nM, the
peak broadened and shifted to a larger size, suggesting aggregation
and polydispersity; eventually a protein precipitate was visible.
The average number of SRPKD per capsid was calculated
according to
n~
S{ S ½  A
C
ð2Þ
in which C and S were input concentrations of capsid and SRPKD
respectively.
While we had expected hyperbolic binding isotherms for n vs
[S]A, assuming [S]=[S]A, the binding curves turned out to be
sigmoidal (Figure 2, blue curve). A likely explanation was
contamination of Cp183 capsid with a small amount of Cp183
dimer. A free dimer with a pair of fully exposed CTDs could bind
SRPKD to form small complexes that did not co-sediment with
capsid. Cp183 dimer has such a poor solubility in the absence of
GuHCl that we do not typically remove dimer from in vitro
assembled Cp183 capsid. However, a residual amount at the nM
level could remain after the capsid reassembly reaction or arise
from dissociation of Cp183 capsids. To test this hypothesis, we
purified capsid by size exclusion chromatography (SEC) prior to
SRPKD titration and found that the initial lag phase in the
titration curve was substantially reduced (Figure 2, red curve).
In light of the dimer-SRPKD side reaction, the binding model
can be described as
CapsidznSRPKDuCapsid:SRPKDn, n~1,2,   ,N ð3Þ
DimerzmSRPKDuDimer:SRPKDm, m~1,2 ð4Þ
.
Correspondingly, the simulation equation for the titration














0{ S ½  A
   2
z4:K
0
D: S ½  A
q z1
ð5Þ
where KD denotes the dissociation constant of each CTD on a free
dimer and C’ is the free dimer concentration (a derivation of
Equation 5 is provided in Supporting Text S1).
Figure 2. Titration of Cp183 capsid by SRPKD. Titrations were
performed to determine the binding constant and stoichiometry of
SRPKD for Cp183 capsids and the binding constant of SRPKD for Cp183
dimer. SRPKD was added to Cp183 assembly reactions, a mixture of
capsids and residual Cp183 dimers (blue curve), or Cp183 assembly
reactions that had been depleted of free dimers by SEC (red curve).
Mixtures were incubated overnight at 4uC and then centrifuged to
pellet capsid and bound SRPKD; SRPKD remaining in the supernatant
was determined by densitometry of SDS-PAGE. Data are reported as the
number of sedimented SRPKD molecules per capsid. Theoretical curves
were fit to the data assuming equivalent non-interacting sites on
capsids or dimers. On average, there were 4963 SRPKD molecules per
capsid binding with 3163 nM dissociation constant and dissociation
constant of 0.660.4 nM for each C-terminus on a free dimer.
doi:10.1371/journal.ppat.1002388.g002
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Based on four independent experiments and curve fits, there are
4963 equivalent and non-interacting SRPKD binding sites on a
capsid. SRPK binds each site with a dissociation constant of
3163 nM. This value is similar to that of the interaction between
SRPKD and a typical substrate SR protein, e.g. 50 nM for ASF/
SF2 [33]. Remarkably, the dissociation constant of SRPKD for
free Cp183 dimer is 0.660.4 nM, an affinity almost two orders of
magnitude stronger, suggesting that Cp183 has evolved to mimic
an ideal SRPK substrate.
SRPKD binds to the exterior of Cp183 capsids
To examine how SRPKD was able to bind the CTD, which is
localized to the interior of a capsid, we determined the structure of
Cp183 capsid saturated with SRPKD. Electron micrographs of
frozen-hydrated Cp183 capsids revealed empty spherical particles
with a diameter of 32 nm (Supporting Figure S2).
To examine the structure of Cp183 without modification by
SRPK, we determined the structure of empty Cp183 to 1.7 nm
resolution. The 3-D image reconstruction of the empty Cp183
capsid showed an overall architecture that is similar to that of both
Cp149 capsid [40] and Cp183 capsid filled with a heterogeneous
mixture of RNA [38]. These particles have a T=4 surface
arrangement with 30 two-fold (quasi-sixfold) vertices; the 120
spikes projecting from the capsid surface are the four-helix bundles
of the dimer interface (Figure 3A–C). Unlike Cp149 capsids, the
outer surface of the control Cp183 structure showed no openings
at icosahedral twofold and fivefold vertices (Figure 3A). In the
Cp183 capsid (Figure 3B and 3C), extra density was observed
within the capsid interior crossing the icosahedral twofold (quasi-
sixfold) vertices. This density, and corresponding density under the
icosahedral fivefolds, is distinct from the relatively smooth inner
surface observed in Cp149 capsids. We attribute this internal
density to the icosahedrally averaged CTDs, as they are expected
to extend from the contiguous shell near these vertices [38,39].
Similar to Cp183 capsid, Cp183 capsid/SRPKD, calculated to
1.4 nm resolution, has a diameter of 32 nm for the contiguous
surface (Supporting Figure S2B) and T=4 icosahedral symmetry.
However, it exhibits 30 exterior funnel-shaped units of density
connecting to the capsid at each icosahedral twofold vertex
(Figure 3D–E). To gain an understanding of the geometry and
occupancy of this additional density, the 3-D density map was
rendered assuming the presence of 240 Cp183 core proteins
assuming an average protein density of 1.36 g/cm
3. The SRPKD
density extended about 4.1 nm from capsid surface, and the funnel
top was about 2.8 nm by 3.8 nm. In the central section of the
Cp183 capsid/SRPKD reconstruction (Figure 3E), it is clear that
this new density is weaker than adjacent capsid density. We also
note that the SRPK density was substantially stronger at lower
resolution (data not shown), suggesting conformational heteroge-
neity. Comparable SRPKD density was also observed in Cp183
reconstructions with lower concentrations of SRPKD (Supporting
Figure S3).
On the interior, in contrast to empty Cp183 capsids, CTD
density under the icosahedral twofold vertex of Cp183 capsid/
SRPKD was extensively remodeled (Figure 3). This is especially
evident in the central section of the reconstructions. In these
images (Figure 3B, E), Cp183 CTD twofold density is absent from
Cp183 capsid/SRPKD.
To examine the external density attributed to SRPKD,w e
calculated a difference map by subtracting the Cp183 map from
that of Cp183 capsid/SRPKD (Figure 4). In this map, SRPKD
appeared to be bound above the icosahedral twofold vertex. The
cryo-EM density map could only fit part of the substrate binding
C-terminal lobe of the SRPKD atomic structure (PDB accession
code: 1WBP) [34]. At lower contour levels, the large lobe could be
fully covered (data not shown). The weakness of the electron
density and its inability to account for the volume of the molecule,
Table 1. Curve fits for titrations of Cp183 capsid by SRPKD.
A B C D Average
N 51.17 45.35 47.97 52.84 4963
KD (nM) 32.03 32.39 27.68 33.40 3163
KD’(nM) 1.21 0.40 0.54 0.25 0.660.4
C’ (nM) 25.09 7.78 18.54 5.71
There were 4 trials of titration: A, B, C and D. In trials B and D, the free dimer
concentration (C’) was depleted by size exclusion chromatography prior to the
titration.
doi:10.1371/journal.ppat.1002388.t001
Figure 3. Three-dimensional structures of Cp183 Capsid and
Cp183 Capsid/SRPKD. Cp183 capsid (A, B, C) and capsid/SRPKD (D, E,
F) are displayed as exterior views (A, D), gray scale central sections (B, E),
and interior views (C, F). Surface-shaded representations were
contoured to account for 100% of the expected protein volume for a
Cp183 capsid. The closed red arrow identifies the external SRPKD
density at twofold vertices; the open red arrow highlights that the
interior density attributable to the CTDs. Binding of SRPKD correlates
with remodeling the capsid interior (compare B, C with E, F) resulting in
the loss of CTD density under twofold vertices. All views are along an
icosahedral twofold axis. The scale bar represents 10 nm.
doi:10.1371/journal.ppat.1002388.g003
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icosahedral.
SRPKD gates Cp183 capsid assembly
The binding data was consistent with the hypothesis that
SRPKD (or a similar kinase) does act as a non-canonical
chaperone, preventing assembly when bound to dimer. We
observed that SRPKD had a higher affinity for dimer than capsid,
suggesting that SRPKD binding should favor the dissociated state.
Furthermore, crowding by SRPKD at twofold vertices was also
expected to disfavor assembly. The missing catalyst for an
assembly reaction is a mechanism to release bound SRPKD,
activating assembly.
To test the hypothesis that SRPK1 could prevent self-assembly,
we examined the effect of SRPKD on in vitro assembly (Figure 5).
Typically, to drive in vitro assembly of empty Cp183 capsids, a
solution of Cp183 dimer, solubilized in non-denaturing concen-
trations of GuHCl, was dialyzed against a GuHCl-free buffer
(reassembly buffer) [26]. Using a reassembly buffer of 0.25 M in
ionic strength, a substantial amount of Cp183 precipitated, while
the rest assembled into capsid as shown by SEC. In comparison,
dialysis of a mixture of a 1:2 molar ratio of Cp183 dimer and
SRPKD in 0.5 M GuHCl against the reassembly buffer resulted in
a soluble mixture in which Cp183 did not precipitate or assemble.
Cp183 and SRPKD co-migrated as a single peak eluting earlier
than either SRPKD or Cp183 dimer (data not shown), indicating
that the two proteins form a stable complex, presumably
dimerNSRPKD or dimerNSRPKD2 or both. SDS-PAGE of the
co-migration peak also indicated more than one SRPKD per
Cp183 dimer (Figure 5A). Thus, these experiments showed that
SRPKD acts to solubilize Cp183 dimer and inhibits its assembly.
To be biologically relevant, this reaction pathway should
include an assembly-reactivation mechanism to remove the
SRPKD protecting group. We reasoned that, like most kinases,
SRPKD would have a much lower affinity for phosphorylated
substrate. Therefore, we dialyzed Cp183/SRPKD complex
against a solution of ATP/Mg
++ to allow phosphorylation of
Cp183. Following dialysis, SEC indicated capsid formation as well
as a large fraction of Cp183 remaining in the complex. The
assignment of the capsid peak was confirmed by electron
microscopy, which showed ,35 nm diameter particles typical for
T=4 HBV in negative stain EM [5]. Like all core protein assembly
reactions, there was also a small population of ,30 nm diameter
particles, presumably with T=3 symmetry [41]. SDS-PAGE of the
capsid peak indicated a much smaller proportion of SRPKD in
reassembled capsid than in the Cp183/SRPKD complex, confirm-
ing that dissociation of SRPKD allows assembly.
SRPKD was expected to phosphorylate Cp183 during ATP-
gated assembly. Based on ESI-MS, the majority of Cp183 in the
capsid peak was decorated with seven phosphate groups
(Figure 5D). A smaller pool of Cp183 was unphosphorylated,
and a minor population of Cp183 had five phosphates.
Unassembled Cp183 that co-eluted with SRPKD also acquired
five or more phosphates (Figure 5E). These observations indicate
that even after phosphorylation, SRPKD can remain associated
with Cp183, though with reduced affinity. From Le Chatelier’s
principle we predict that gradual release of phosphorylated Cp183
will lead to further capsid assembly. Indeed, phosphorylated
Cp183-SRPKD fractions slowly assembled into EM-observable
capsids over a few days.
Discussion
In our in vitro experiments, we tested hypothetical regulatory
mechanisms of the HBV lifecycle by employing SRPKD for
unconventional functions: (i) a probe that labels the CTD exposed
on a HBV capsid, demonstrating that the CTD location is
dynamic; (ii) a non-canonical chaperone that gates HBV capsid
assembly. SRPK1 or SRPK2 affect Cp183 phosphorylation and
assembly in vivo [42,43].
Figure 4. The difference map and modeling of SRPKD on Cp183 Capsid. (A) To isolate the density attributable to SRPKD, a difference map of
SRPKD (red color) was calculated by subtracting Cp183 Capsid from Cp183 capsid/SRPKD and superimposed on the corresponding region of the 3-D
reconstruction of Cp183 Capsid. The resulting densities of SRPKD were found located at each twofold axis. The bar represents 10 nm. (B) Cryo-EM
density of Cp183 capsid/SRPKD fitted with SRPKD coordinates (as shown in the cartoon representation) viewed at twofold position. The 3-D
reconstructions rendered in isosurface and isomesh modes represent 100% contour and a 1 s contour, respectively. The fitting was performed
manually to place the SRPKD active site close to the twofold pore and maximize envelopment of the large lobe of SRPKD in cryo-EM density. The
twofold axis is marked with a dashed line.
doi:10.1371/journal.ppat.1002388.g004
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the core protein or engaging the CTD with RNA eliminates the
SRPKD-capsid interaction (Supporting Figure S1). In capsids, the
CTDs are localized to the capsid interior, extending from the
assembly domain of the core protein near the pores at capsid
twofold and fivefold vertices [12,39]. There are potentially 240
SRPKD-binding CTDs per T=4 capsid. However, titration of
Cp183 capsid by SRPKD fits a model of 4963 equivalent and
independent SRPKD binding sites per capsid (Figure 2, Table 1).
Image reconstructions only show 30 units of relatively weak
SRPKD density on the capsid exterior at the twofold vertices
(Figure 3 and 4). The number difference between solution
Figure 5. In vitro SRPKD-gated HBV capsid assembly. SRPKD was used as an in vitro chaperone to prevent Cp183 aggregation and regulate
Cp183 self-assembly. (A) Size exclusion chromatographs of Cp183 capsid assembly products. The insets show SDS-PAGE of the indicated SEC
fractions. Cp183 capsid assembly was normally induced by dialyzing GuHCl from Cp183 dimer solution, resulting in reassembled capsid eluting at
,8 ml and a significant loss of Cp183 to precipitation (green). Mixing SRPKD and Cp183 dimer prior to dialysis prevented aggregation or capsid
assembly; instead a stable soluble complex formed and eluted at ,15 ml (blue). Subsequent dialysis of the Cp183 capsid/SRPKD complex against
ATP/Mg
++ resulted in a mixture of capsid, complex, and presumably free SRPKD (red). (B) Negative stained TEM of the capsid fraction from an SRPKD-
gated Cp183 assembly reaction shows morphologically normal HBV capsids. The majority of the particles are ,35 nm in diameter with a minor
,30 nm diameter population. The scale bar is 100 nm. (C) Table of species identified in the mass spectra shown in panels d and e. (D) MS of the
capsid fraction from an SRPKD-gated assembly reaction. Most of the Cp183 from the capsid fraction was phosphorylated at seven sites, with a
relatively small portion of unphosphorylated and partially phosphorylated protein. (E) MS of the lower molecular weight complex fraction after
SRPKD-gated assembly. Most Cp183 was phosphorylated at 5 to 7 sites; the relatively large fraction of partially phosphorylated Cp183 in this pool
suggests that it is more likely to remain bound to SRPKD.
doi:10.1371/journal.ppat.1002388.g005
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binding at each of the 30 twofold vertices, each of which has six
CTDs. Because of increasing steric hindrance, the binding
constants at each site probably decrease as more SRPKDs bind.
The curve fit describes the simplest model consistent with the
binding data; a more complex model that includes multiple
binding constants for multiple SRPKDs per vertex could easily fit
but would be inconclusive. Nonetheless, the binding data do
indicate that at least two SRPKD molecules can bind at each
twofold. The weakness of the SRPKD density is attributable to
disorder: there are six non-equivalent CTDs around a twofold
vertex, each of which carries seven phosphorylation sites (Figure 1)
and is likely to be very flexible. After 60-fold averaging, the large
volume that could be occupied by one or more bound SRPKDsi s
represented by a small high occupancy core (Figure 4).
Binding of SRPKD to the CTDs of a capsid requires exposure
of the CTDs to the outer surface, at least transiently, since SRPKD
is too big (.2.9 nm in any dimension) [34] to fit through the
capsid pores (,1.5 nm at twofold axes and , 0.3 nm at fivefold
axes) [39]. Transient exposure of CTDs has been previously
suggested to allow additional interactions with host machinery to
regulate the HBV life cycle [44]. This hypothesis is supported by
correlations that associate CTD phosphorylation with intracellular
trafficking [20,23–25]. As a more direct observation, this paper
visually demonstrates the CTD exposure and its interaction with a
host protein.
Furthermore, our study suggests a mechanism for the regulation
of CTD exposure and accessibility which can signal core
maturation (Figure 6). We observed that in empty capsids the
CTDs were able to bind SRPKD (Supporting Figure S1).
However, if the capsid was filled with RNA, no binding was
observed. Our interpretation is that the negatively charged RNA
retains the basic CTDs inside the capsid and prevents external-
ization. In the context of the HBV life cycle, a control mechanism
is necessary to distinguish mature cores from immature ones; we
suggest this is mechanism is based on exposure of the CTD. Only
mature HBV cores are enveloped and secreted [11,12] or
transported to the nucleus [22]. We speculate that reverse
transcription, which occurs within the HBV core, allows exposure
of CTDs. The interaction between CTDs and single stranded
RNA, which is very flexible and can contort to interact with all
CTDs, is able to restrict CTD exposure. The partially double
stranded DNA genome of the mature core is expected to be much
less flexible and much less able to engage CTDs; thus, reverse
transcription will allow exposure of at least some of the 240 CTDs
in each capsid. In this paper we have shown that RNA-filled
capsids do not appreciably bind SRPKD. Similarly, it was
observed that RNA-filled capsids are not appreciably phosphor-
ylated by exogenous protein kinase C unless they are partially
disassembled, whereas kinase activity that co-purifies with virions
is able to add two to four phosphates per virion (as
32P), indicating
the availability of only one to four CTDs out of the 240 in a capsid
[45]. A maturation-dependent change in CTD accessibility would
allow cores to bind proteins such as SRPK or importin a/b to
direct trafficking [20–22]. Accessibility of the CTD is likely, as it is
the CTD that carries the HBV core nuclear localization signal
[46,47].
There are two explanations for the ability of the CTD to be
exposed in our experiments: breathing/partial opening of the
capsid or exit of the CTD through the pre-existing hole on the
twofold. We find that breathing alone is inadequate to explain
CTD exposure. It has been proposed that capsid dynamics,
breathing modes, can facilitate CTD exposure [44]. Breathing
modes have been shown to expose buried and internal peptide
segments in flock house virus [48], rhinovirus [49], and HBV [44].
In HBV, breathing modes appear to involve a partial unfolding of
the core protein near the C-terminus of the assembly domain,
exposing a buried residue to proteolytic digestion. The unfolding
equilibrium constants for Cp149 capsid between 19uC and 37uC
are documented [44]. By extrapolation, we can obtain the value
for our experimental condition, 4uC and it is 6610
25. This
number tells the chance for a CTD to become externalized
through the breathing mode. In comparison, our titration data
provide an experimental value for CTD exposure rate if we
attribute the affinity difference between capsid/SRPKD and
dimer/SRPKD to the availability of the core protein CTDs.
The dissociation constant for capsid/SRPKD and dimer/SRPKD
are 31 nM and 0.6 nM, respectively; hence the exposure rate of a
CTD at a twofold vertex is 0.6/31=0.02. As there are 6 CTDs
around a twofold axis, the exposure rate contributed by each CTD
is about 0.02/6=0.003. This value is two orders of magnitude
higher than the unfolding rate of a Cp149 capsid. The discrepancy
may reflect that Cp183 is more labile than Cp149, or indicate that
the highly flexible CTDs can simply thread through the large
capsid pore at a twofold vertex without involving a breathing
mode.
We have demonstrated a SRPKD-gated capsid assembly
mechanism in vitro. In vivo, a different protein may serve as a
chaperone to minimize Cp183 self-assembly at an inappropriate
time. However, SRPK1 and SRPK2 are particularly attractive
candidates for the regulatory chaperone, as it can be released by
phosphorylation, resulting in an assembly reactivation mechanism
(though we cannot exclude other kinases with high affinity for
substrate). It has been previously observed that SRPK2 co-
immunoprecipitates with HBV core protein in the context of huh7
cells [42]. Similarly, overexpression of either SRPK1 or SRPK2
inhibits replication of HBV, with the stronger inhibitory effect
associated with SRPK2 [43]. We note that phosphorylation does
not cause SRPKD to release Cp183; it weakens a very strong
association. Some of the phosphorylated Cp183 did not proceed to
self-assembly immediately; rather, it stayed bound to SRPKD in a
soluble complex. Thus, even after phosphorylation, SRPKD
retains a useful chaperone activity (Figure 6). The observation of
continued assembly of the SEC-purified phosphorylated Cp183/
SRPKD complex over several days supports this hypothesis. In the
presence of excess SRPK mass action would favor the persistence
of the phosphorylated Cp183/SRPK complex. Consequently self-
assembly of Cp183 would be kinetically and thermodynamically
inhibited. Assembly activation would require a specific high
affinity nucleating complex to displace weakly associated SRPK
and initiate assembly. In vivo, the pgRNANRT complex may serve
this role.
Materials and Methods
Cp183 dimer and capsids
Cp183 capsids filled with host RNA were harvested from an E.
Coli expression system [37]. Cp183 dimers were purified as
previously described [26]. Briefly, capsids were destabilized in
1.5 M guanidine, 0.5 M LiCl, 10 mM DTT, and 20 mM Tris-
HCl at pH 7.4 (disassembly buffer). In disassembly buffer, most
RNA was sedimented with Li
+ and the residual amount was
separated from Cp183 dimer by SEC. The purified Cp183 dimer
was stored in disassembly buffer and the concentration was
determined by UV absorbance (e280=60,900 M
21Ncm
21) [50].
To generate empty Cp183 capsids, Cp183 dimer was dialyzed
against 0.25 M NaCl, 10 mM DTT and 20 mM Tris-HCl at
pH 7.4 (reassembly buffer) [26]. Some samples of reassembled
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Superpose 6 column. Capsid concentration was measured by
scattering-corrected UV absorbance as previously described [50].
When necessary, purified capsids were concentrated by adsorption
to a Mono-Q column, from which they were eluted at by ,0.5 M
NaCl. Reassembled empty capsids were stored at 280uCi n
reassembly buffer with 30% glycerol. To validate the integrity of
stored Cp183 capsids they were examined by SDS-PAGE, EM,
dynamic light scattering, and affinity towards SRPKA ¨. Stored
Cp183 capsids showed no evidence of proteolytic degradation by
SDS-PAGE. By negative stain EM and cryo-EM particle
morphology remained consistent with numerous previously
published micrographs (see Supporting Figures S 2). The diameter
of stored capsid (ca 40 nm), by dynamic light scattering, was the
same as freshly prepared capsid, indicating minimal aggregation.
Both freshly prepared and stored Cp183 capsids showed high
affinity for SRPKD (experiments shown in Supporting Figure S1
used fresh capsids, experiments shown in Figure 2 used stored
capsids).
SRPKD preparation
A plasmid coding SRPKD was a gift from Dr Gourisankar
Ghosh (UCSD). Protein expression and purification through a
His-Trap column has been described [33]. For further purifica-
tion, the eluate from the His-Trap column was loaded onto a
Mono-Q column, from which SRPKD was eluted at 0.2 M NaCl.
The protein concentration was calculated from UV absorbance.
The extinction coefficient, e280=74,745 M
21Ncm
21, was deter-
mined using the Edelhoch method [51] and confirmed by cysteine
reaction with dithionitrobenzoic acid. When necessary, purified
SRPKD was concentrated using a His-Trap Column.
SRPKD-capsid binding assay on a His-Trap column
For these experiments, purified capsids (reassembled Cp183
capsids, reassembled Cp149 capsids [14] and Cp183 capsids filled
with E. Coli RNA [37]) and SRPKD were all exchanged into
20 mM imidazole, 0.3 M NaCl and 20 mM phosphate at pH 7.4
(buffer A). Samples of SRPKA ¨ were adsorbed onto a 1 ml
His-Trap column and the column was equilibrated with buffer A
at 4uC. A capsid sample (0.1 ml) was then loaded on the column,
followed by a programmed elution using 5 ml of buffer A, 1 ml of
gradient change from buffer A to buffer B (0.5 M imidazole,
0.3 M NaCl and 20 mM phosphate at pH 7.4) and 5 ml of 100%
buffer B. Control runs were executed by replacing either SRPKD
or the capsid sample for an equal volume of buffer A. Fractions
from each run were tested by SDS-PAGE.
Titration of Cp183 capsid by SRPK
Purified SRPKD and Cp183 capsids were exchanged into
0.30 M NaCl, 10 mM DTT and 20 mM Tris-HCl at pH 7.4
(buffer R). A series of 150 ml reactions, consisting of Cp183 capsid
(4 mM dimer concentration) and SRPKD ranging from 60 nM to
2 mM all in buffer R, were incubated overnight at 4uCi n
BECKMAN Polycarbonate Centrifuge Tubes. The tubes were
then centrifuged in Optima
TM MAX-XP Ultracentrifuge (BECK-
MAN COULTER) at 4uC and 150,000 g for half an hour. Under
this condition, .95% of the capsids sedimented while .95% of
free SRPKD stayed in the supernatant. To determine the amount
of SRPKD remaining in solution after centrifugation, supernatants
and SRPKD concentration standards were loaded onto 10% SDS-
PAGE. The gels were silver stained and the densities of bands in
scanned gels were quantified using ImageJ.
Electron microscopy and image processing
SRPKD-decorated Cp183 capsid was prepared by mixing
5.6 mM SRPKD and 5.8 mM (dimer concentration) Cp183 capsid
in 0.53 M NaCl, 10 mM DTT and 20 mM Tris-HCl at pH 7.4.
The reaction was incubated at 4uC for 4 days prior to cryo-EM.
Specimens for electron cryo-EM were vitrified and imaged by
the well established procedures as previously described [52].
Briefly, a 3.5 ı `l drop of sample was applied to a glow-discharged
holey carbon-coated grid (Quantifoil R2/2). The grid was then
plunged into liquid ethane cooled by liquid nitrogen using an FEI
Vitrobot
TM. All subsequent steps were carried out with the
specimens kept below 2170uC to avoid the devitrification. The
grid was transferred to a Gatan 626DH cryo-holder (Gatan Inc.,
Figure 6. Scheme describing SRPK-gated mechanism of HBV core and capsid assembly. Binding of SRPK to unphosphorylated Cp183
prevents self-assembly and packaging nucleic acid. Subsequent phosphorylation weakens SRPK association to slowly release free Cp183 to form
capsid. Even modest concentrations of free SRPK should suppress the concentration of free Cp183 and therefore prevent capsid assembly. In vivo, a
likely catalyst of Cp183 release is reverse transcriptase-bound pgRNA that can displace weakly bound SRPK and induces assembly resulting in
packaging specificity.
doi:10.1371/journal.ppat.1002388.g006
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(JEOL Ltd., Japan) operated at 300 kV. Images were recorded at
multiple defocuses on a Gatan UltraScanTM 4000 4k x 4k CCD
camera at a magnification of 80,000x for Cp183 capsid and
40,000x for Cp183 capsid/SRPKD under low-dose condition
(#14 e-/A ˚ 2). The pixel size was 0.1484 nm for capsid and for
0.2940 nm for capsid-SRPKD.
Selected images with minimum astigmatism and drift were
processed using EMAN2 (v 2.0) [53] and AUTO3DEM (v 3.15)
software packages [54]. Particles were semi-automatically picked
using e2boxer.py. The initial 3-D model was generated using the
ab initio random model reconstruction method implemented in
AUTO3DEM [54]. Origin and orientation searches were carried
out iteratively using PPFT and further refined by PO2R [55]. The
final 3-D maps of Cp183 capsid and Cp183 capsid/SRPKD were
computed from 955 and 4399 particles using P3DR, respectively.
The estimated resolution for Cp183 capsid was 17.4 A ˚ and for
Cp183 capsid/SRPKD was 14.2 A ˚ using Fourier shell correlation
at 0.5, calculated in EMAN2, as the criteria (Supporting Figure
S4). Reconstructions were visualized using Robem, Chimera [56]
and PyMOL [57].
To calculate a difference map, subtracting Cp183 capsid from
Cp183 capsid/SRPKD, the region from radius 12.5–16.0 nm was
used to scale the magnification and density. There was no
detectable difference in the diameters of the capsids in the two
reconstructions. In the resulting difference map, the solvent density
was set to zero for radii smaller than inner surface (radius 11.2 nm)
and for radii beyond the tip of the funnel-shaped density (radius
20.3 nm) (Figure 4).
In vitro assay of SRPKA ¨-gated HBV capsid assembly
Cp183 capsid assembly was set up in three ways for comparison:
(i) 5.3 mM of Cp183 dimer in disassembly buffer was dialyzed
overnight against reassembly buffer. (ii) 5.3 mM of Cp183 dimer
was mixed with 11.2 mM of SRPKA ¨ in disassembly buffer and
together they were dialyzed overnight against the reassembly
buffer. (iii) The product from (ii), presumably a complex of Cp183
dimer with two SRPK molecules, was dialyzed against reassembly
buffer plus 10 mM Mg
2+ and 0.5 mM ATP. The reaction
products were resolved by SEC, using a Superose 6 column, and
the fractions were tested using SDS-PAGE.
Accession codes
The SRPKD and Cp149 atomic structures and sequences are
available from the protein data bank (PDB accession codes: 1WBP
and 2G33, respectively) [34,58]. Cp183 adds 34 C-terminal
residues to Cp149; the Swiss Protein database accession code is
P03147.1. The cryo-EM density maps of T=4 HBV Cp183
capsid and Cp183 capsid/SRPKD have been deposited to
EMDataBank.org. The EMDB accession codes are EMD-1969
and EMD-1968 respectively.
Supporting Information
Figure S1 Capsid binding to column-immobilized
SRPKD. (A) Binding assays to show that empty Cp183 capsids
interact with SRPKD, in contrast to empty Cp149 capsids and
RNA-filled Cp183 capsids. We preloaded His-tagged SRPKD
onto a His-trap (GE Health Sciences) column, and then ran a
capsid solution through. Bound protein was eluted (solid curves)
with an imidazole gradient (pink curve); fractions were evaluated
by SDS-PAGE (insets). As a control, binding of capsid and
SRPKD were examined separately, and the chromatograms were
summed to simulate independent elution (dotted lines). (B) EM
monitoring the Cp183 capsid to pass through SRPKD-loaded His-
trap column. Cp183 appeared as intact capsids either after freely
passing through the column (left) or binding to SRPKD (right).
(TIF)
Figure S2 Cryo-EM micrographs of Cp183 Capsid and
Cp183 capsid/SRPKD. Cryo-EM images of (a) Cp183 capsid
and (b) Cp183 capsid/SRPKD embedded in vitreous ice. The
Cp183 capsid/SRPKD exhibited some thorn-like density (arrows)
extending from the particle surface. The scale bar is 50 nm.
(TIF)
Figure S3 3-D structure of Cp183 capsid/SRPKD at
lower occupancy. This sample was obtained from near the
midpoint of a Cp183 capsid titration where on average
approximately 30 SRPKD were bound per Cp183 Capsid. A
total of 622 particles were used to compute this 3-D reconstruction
to 2.2 nm resolution. Surface-shaded representations of the outer
surfaces (a) and inner surfaces (c) of Cp183 capsid/SRPKD viewed
along the icosahedral twofold axis at 100% expected mass for
Cp183 Capsid. The central section of Cp183 capsid/SRPKD
volume was shown in (b). These results are essentially the same as
those shown in figure 3, though at lower resolution. The scale bar
is 5 nm.
(TIF)
Figure S4 Resolution estimated by Fourier shell corre-
lation. The particles used to compute the final 3-D reconstruc-
tions were evenly divided into two sub-datasets and reconstructed.
The resolutions of the reconstructions were defined as the spatial
frequency where the correlation between Fourier terms was
#50%.
(TIF)
Text S1 Derivation of the binding isotherm of SRPK for
mixed Cp183 dimer and capsid.
(DOC)
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